EpimAb Biotherapeutics announced Wednesday that it has raised $74 million in its Series B funding, extending the streak of private fundraising among Chinese biopharmaceutical firms specialising in anti-cancer drug research.
¬ Haymarket Media Limited. All rights reserved.
